Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DK210 (EGFR) in advanced solid EGFR+ tumors
NCT05704985Phase 1Active, not recruiting
- Sponsor
- Deka Biosciences
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Immunomodulatory ADCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of DK210 (EGFR) in solid tumor, colorectal cancer (CRC), pancreatic cancer (PC) and 5 more (4 arms), sponsored by Deka Biosciences. Primary endpoints: Incidence of Adverse Events at 90 days and Recommended Phase 2 Dose at 90 days. Started Apr 2023; status: active, not recruiting.
02
Drugs
DK210 (EGFR)
03
Conditions
solid tumorcolorectal cancer (CRC)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05704985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704985.